EssilorLuxottica completes acquisition of Optegra EssilorLuxottica completes acquisition of Optegra Paris, France (1 October 2025) – EssilorLuxottica announces that it has successfully completed the from MidEuropa. Under the Optegra, Lexum and Iris brands, Optegra is a fast-growing and highly integrated ophthalmology platform operating an extensive network of over 70 eye hospitals and diagnostic facilities in five key European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. A natural fit for EssilorLuxottica’s expanding med-tech portfolio, this acquisition repres...
EssilorLuxottica finalise l’acquisition d’Optegra EssilorLuxottica finalise l’acquisition d’Optegra Paris, France (1er octobre 2025) – EssilorLuxottica annonce la finalisation de auprès de MidEuropa. Avec les marques Optegra, Lexum et Iris, Optegra est une plateforme d'ophtalmologie à forte croissance et hautement intégrée, opérant un vaste réseau de plus de 70 hôpitaux ophtalmologiques et centres de diagnostic dans cinq marchés européens clés : le Royaume-Uni, la République tchèque, la Pologne, la Slovaquie et les Pays-Bas. Très complémentaire avec le portefeuille med-tech d'EssilorLu...
EssilorLuxottica completa l’acquisizione del gruppo Optegra EssilorLuxottica completa l’acquisizione del gruppo Optegra Parigi, Francia (1 ottobre 2025) – EssilorLuxottica annuncia di aver completato l’ da MidEuropa. Con i marchi Optegra, Lexum e Iris, il gruppo Optegra è una piattaforma oftalmica perfettamente integrata e in forte espansione. Attualmente opera una vasta rete di oltre 70 ospedali oftalmici e centri diagnostici in cinque mercati europei strategici: Regno Unito, Repubblica Ceca, Polonia, Slovacchia e Paesi Bassi. L’acquisizione si inserisce perfettamente nel portafoglio ...
EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States EssilorLuxottica’s lens is clinically proven to slow myopia progression in children1,2 Paris, France (25 September 2025) – EssilorLuxottica today announced the U.S. Food and Drug Administration (FDA) has granted market authorization for its Essilor Stellest lens using the De Novo pathway. This follows the product’s earlier recognition with the FDA granting designation as a Breakt...
EssilorLuxottica: Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis L’efficacité du verre d'EssilorLuxottica pour ralentir la progression de la myopie infantile est cliniquement prouvée1,2 Paris, France (25 septembre, 2025) – EssilorLuxottica a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis lui a accordé une autorisation de mise sur le marché pour son verre Ess...
EssilorLuxottica: Essilor Stellest sono le prime e uniche lenti oftalmiche autorizzate alla vendita dall’FDA negli Stati Uniti Essilor Stellest sono le prime e uniche lenti oftalmiche autorizzate alla vendita dall’FDA negli Stati Uniti Studi clinici dimostrano l’efficacia delle lenti di EssilorLuxottica nel rallentare la progressione della miopia nei bambini1,2 Parigi, Francia (25 settembre 2025) – EssilorLuxottica annuncia di aver ottenuto l’autorizzazione dalla Food and Drug Administration (FDA) alla commercializzazione delle lenti Essilor Stellest grazie al percorso regolatorio De Nov...
A director at Iberdrola S.A. bought 5,183 shares at 15.628EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.